Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL

Abstract Introduction The study was conducted to assess the impact of depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL (DMPA-SC 104) on body weight. Methods Changes in weight from pretreatment were analyzed using data from two 1-year, noncomparative trials of DMPA-SC 104 (North/South American, N =722; European/Asian, N =1065) and a 3-year, randomized study (SC/IM) comparing DMPA-SC 104 ( N =266) with the DMPA intramuscular injection 150 mg/mL (DMPA-IM 150). For each study, additional analyses were conducted for changes in body weight by age ( 35 years) and body mass index (BMI) (≤25, >25 to ≤30 and >30 kg/m 2 ) subgroups. Results In both 1-year trials, the mean (±SD) weight gain at month 12 was Conclusion DMPA-SC 104 was associated with modest weight gain in most women.